FP
MYGN icon

Foundry Partners’s Myriad Genetics MYGN Stock Holding History

Foundry Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,403
Closed -$283K – 406
2019
Q4 		$283K Buy
10,403
+1,328
+15% +$36.5K 0.01% 372
2019
Q3 		$260K Sell
9,075
-1,725
-16% -$50.3K 0.01% 373
2019
Q2 		$300K Buy
10,800
+1,400
+15% +$39.5K 0.01% 370
2019
Q1 		$312K Buy
+9,400
New +$286K 0.01% 368
2018
Q2 		– Sell
-16,125
Closed -$476K – 400
2018
Q1 		$476K Buy
16,125
+6,400
+66% +$217K 0.02% 350
2017
Q4 		$334K Sell
9,725
-3,825
-28% -$129K 0.01% 361
2017
Q3 		$490K Sell
13,550
-10,700
-44% -$305K 0.02% 346
2017
Q2 		$627K Buy
24,250
+1,750
+8% +$37.1K 0.03% 348
2017
Q1 		$432K Buy
22,500
+775
+4% +$13.7K 0.02% 378
2016
Q4 		$362K Buy
+21,725
New +$393K 0.02% 399

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Foundry Partners's MYGN Position: Q1 2020 in Review

Foundry Partners sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 10,403 shares — an estimated $283K sold.

Foundry Partners first reported a position in MYGN in Q4 2016 and held it in 10 quarters. The position peaked at $627K in Q2 2017. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

  • Foundry Partners reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
  • Foundry Partners sold 10,403 Myriad Genetics shares in Q1 2020, an estimated $283K.
  • Foundry Partners first reported a position in Myriad Genetics in Q4 2016 and held it in 10 quarters.
  • Foundry Partners's Myriad Genetics position peaked at $627K in Q2 2017.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Foundry Partners's 13F filing for Q1 2020, filed 8 May 2020.